A common liver condition may be considerably more complicated than previously understood. New research from Mayo Clinic, conducted in collaboration with Virginia Tech, has identified five biologically distinct forms of metabolic dysfunction-associated steatotic liver disease (MASLD).

Each form appears to follow different biological pathways and carries varying risks of serious complications.

Why One Diagnosis May Represent Different Conditions

MASLD develops when excessive lipid material accumulates in the liver, often alongside metabolic problems such as insulin resistance and diabetes. Many affected individuals experience few noticeable symptoms during the early stages, making the condition difficult to recognize without medical testing.

In some cases, the disease progresses toward inflammation, tissue scarring, and severe liver damage. However, progression is not identical for everyone. Certain patients experience serious complications despite having relatively few conventional metabolic risk factors. This variation has raised an important scientific question: could different biological mechanisms be responsible for conditions currently grouped under the same diagnosis?

The Mayo Clinic investigation provides evidence supporting this possibility. Its researchers identified five distinct subtypes with different genetic characteristics, clinical measurements, and patterns of disease progression.

How Researchers Identified Five Subtypes

The research team examined genetic sequencing information and detailed medical records from more than 4,600 patients diagnosed with MASLD. The collected information included liver enzyme measurements, body mass index, blood lipid levels, and medical conditions such as diabetes, depression, and sleep apnea. Researchers combined these measurements using computational models designed to recognize patterns that might otherwise remain difficult to identify.

The analysis revealed five groups with different biological characteristics. Rather than relying exclusively on symptoms or conventional clinical measurements, the method considered how inherited genetic differences interacted with other health indicators. This approach is important because two patients can receive the same diagnosis while having substantially different underlying biological processes.

Genetic Differences May Reveal Hidden Risks

One of the most significant findings involved genetic subtypes associated with more advanced disease progression. Some patients appeared to have inherited biological characteristics that increased their likelihood of developing severe liver complications. Notably, these risks could remain present even when conventional metabolic warning signs were limited.

This observation challenges the assumption that commonly recognized risk factors provide a complete picture of disease progression. Genetic information may eventually help clinicians identify patients who require closer monitoring, even when routine assessments do not indicate an especially high level of concern. However, genetic findings should not be interpreted as a definite prediction of an individual's future health.

Connections With Other Health Conditions

The investigation also identified associations between particular MASLD subtypes and several conditions beyond the liver, including depression, sleep apnea, and migraine. These relationships suggest that different biological pathways may influence several aspects of health simultaneously.

For example, sleep apnea can involve repeated interruptions in breathing during sleep, potentially affecting oxygen availability and metabolic regulation. Depression may also interact with sleep patterns, physical activity, and other health behaviors. Nevertheless, the findings do not establish that MASLD directly causes these conditions. Instead, they reveal connections that deserve further investigation and may help researchers understand why certain health problems occur together.

Expert Insight

Shulan Tian, PhD, co-senior author of the study and a bioinformatician at Mayo Clinic, explained how separating the newly identified subtypes could improve future medical approaches. In Mayo Clinic's official research announcement, Tian stated: “Once you separate these subtypes, you can start to match treatments to the biology that's actually driving the disease.”

Could Personalized Treatment Improve Future Care?

The findings may eventually support more targeted screening and treatment strategies. Patients with genetic patterns associated with faster progression could receive closer monitoring, while treatment plans might be adjusted according to the mechanisms involved. Researchers also intend to investigate whether the five subtypes respond differently to available therapies, including GLP-1 receptor agonists, which are used in managing certain metabolic conditions.

The Mayo Clinic investigation provides evidence that MASLD consists of five biologically distinct subtypes rather than one uniform condition. By combining genetic information with detailed medical records from more than 4,600 patients, researchers identified differences that may help explain variations in disease progression and complications.

Although further validation is necessary, the findings represent an important step toward more personalized liver care. Better recognition of individual biological patterns could eventually support earlier risk assessment, more appropriate monitoring, and treatment strategies based on the specific processes involved.